GeneDx Holdings Corp. · NASDAQ:WGS
GeneDx — Sema4 — J.P. Morgan Healthcare Conference 2022
22 slides from GeneDx's conference presentation, January 2022
Slide 1: Investor Presentation J.P. Morgan Healthcare Conference
Investor Presentation J.P. Morgan Healthcare Conference January 2022
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the future that, for
Slide 3: A Patient-Centered Health Intelligence Company Leveraging Genomics and AI
A Patient-Centered Health Intelligence Company Leveraging Genomics and AI
Slide 4: Corporate Snapshot
Corporate Snapshot World-class team 2021 guidance Unrivaled patient access Massive scale in data Massive scale in NGS 1,200+ employees $204-206M total 12M de-identified records 46+ petabytes 250,000+3 revenue2 500k+ w/ genomic profiles managed growing at an tests annually 160+ MDs/PhD’s1 acceleratin
Slide 5: The Problem
The Problem Rapid advances in Genomics & AI... ...but limited impact on patients 5
Slide 6: Our Solution: A Holistic Approach to Patient Care
Our Solution: A Holistic Approach to Patient Care… ECS, NIPT, Hereditary Cancer, Use of multiple methods and and Natalis solutions designed technologies, each with with flexibility to meet accuracy of >99% patient needs Cutting-edge Flexible, science and in-depth methodologies genomic solutions Cont
Slide 7: Combined with Centrellis, our Flywheel for Patient Data and Insights
…Combined with Centrellis, our Flywheel for Patient Data and Insights Enhanced Data Feed Channels Insights & Engagement Health Systems Clinical Trials EMR, Imaging, Molecular, Claims Clinical Decision Support Third Parties Population Health Models EMR, Imaging, Molecular, Claims Patients & Provider
Slide 8: Deep Partnership with Health Systems
Deep Partnership with Health Systems (Beginning with learning-based partners) Conventional Genomics Model narrow menu Enabling Precision Medicine sold direct to physicians as the Standard of Care no (or limited) data integration no or limited patient engagement 8
Slide 9: Evolution Towards a Platform of Algorithms
Evolution Towards a Platform of Algorithms Increased Value to MONETIZE INFORMATION Patients, Providers, PLATFORM TO QUERY Pharma FOR INSIGHTS Matching patients to products and services (moving beyond providers and life science) SECONDARY INSIGHTS Novel disease models that inform clinical care and tr
Slide 10: The Value of Data: Must be Longitudinal and Prescriptive
The Value of Data: Must be Longitudinal and Prescriptive MULTI-DISEASE Collected over time + Curated disease specific clinical notes ENRICHED DATA RICHNESS LONGITUDINAL Collected over time + Curated clinical notes LONGITUDINAL Collected over time EPISODIC Point-in-time PATIENT IMPACT DESCRIPTIVE DIA
Slide 11: NorthShore: The First Six Months
NorthShore: The First Six Months
Slide 12: Enabling Biopharma Partners and Customers
Enabling Biopharma Partners and Customers SEMA4 OFFERING Deep Partnerships Clinical trial matching SaaS-based licensing leveraging data science LEAD IDENTIFICATION EARLY CLINICAL PROTOCOL OPTIMIZATION REAL WORLD DATA Drive increased probability of Reduce trial duration, Maximize trial opportunity, C
Slide 13: Health System Partnerships Helping Accelerate Biopharma Partnerships
Health System Partnerships Helping Accelerate Biopharma Partnerships Molecular Profiling and Real-World Evidence CONTENT MOLECULAR INFORMATION Patient Id and Recruitment Genomic, Proteomic, Cellular IMAGING DATA Drug Discovery Collaboration MR, CT, XR Centrellis® CLINICAL DATA EMR, Claims, Registrie
Slide 14: 4Q Update: Strong Close to 2021
4Q Update: Strong Close to 20211 4Q Resulted Volume 4Q Total Revenue 4Q Balance Sheet Will exceed 80,000 tests Expects total revenues in ~$400 million in Cash & excluding COVID-19 the range of $50-52 million Cash Equivalents as of 12/31/21 Guidance was 73,000 - 79,0002 Guidance was $46.6 - 49.6 mill
Slide 15: Operational Improvements: Key Highlights and Future Focus
Operational Improvements: Key Highlights and Future Focus Lab Commercial Pharma Operations Reach & Data Key Actions Key Actions Key Actions § Hired seasoned SVP Lab § Increased salesforce headcount § Hired Chief Data & Chief Science Operations by 84% in 2021 Officers § Key investments in Lab § Annou
Slide 16: Capital Allocation
Capital Allocation Significant Capital Resources to Acquisition Criteria Include Drive Long Term Strategy Enhance Our Reach into Health Systems $400M Cash & Cash Equivalents $125M Revolver, undrawn1 Enhance Our Data Capabilities Commercial Revenue 1 Our estimates of our fourth quarter 2021 cash and
Slide 17: Thank you
Thank you
Slide 18: Appendix
Appendix
Slide 19: Historical COVID Revenue Mix
Historical COVID Revenue Mix % of Total Revenue1 1Q20 2Q20 3Q20 FY20 1Q21 2Q21 3Q21 Diagnostic Test 99% 93% 84% 79% 73% 87% 86% COVID 0% 6% 14% 18% 25% 8% 10% Other 1% 1% 2% 2% 2% 4% 4% 19 1 Certain periods do not add to 100% due to rounding
Slide 20: Non-GAAP Gross Margin Reconciliation
Non-GAAP Gross Margin Reconciliation USD Millions 20
Slide 21: Non-GAAP EBITDA Reconciliation
Non-GAAP EBITDA Reconciliation USD Millions 21
Slide 22: Sema4 Nasdaq Listed
SMFR Semat Nasdaq Listed sema4